Latest Pharmaceuticals News

Page 61 of 72
Acrux Limited has appointed John Warmbrunn as its new CEO and Managing Director, signaling a strategic push for international expansion and product development starting June 2025.
Ada Torres
Ada Torres
7 May 2025
CLINUVEL Pharmaceuticals has completed recruitment for its Phase III trial of SCENESSE® in vitiligo patients with darker skin types, setting the stage for first results in late 2026. Early clinical observations suggest promising repigmentation outcomes.
Ada Torres
Ada Torres
7 May 2025
Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.
Ada Torres
Ada Torres
6 May 2025
Sigma Healthcare’s recent merger with Chemist Warehouse Group is delivering strong earnings growth, with Normalised EBIT rising 36% in the first half of FY25. Transaction costs remain significant but the combined group’s outlook appears robust.
Ada Torres
Ada Torres
6 May 2025
Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.
Ada Torres
Ada Torres
5 May 2025
Nyrada Inc. has cleared the Safety Review Committee’s scrutiny for its Phase I clinical trial, progressing to the third dosing cohort of its promising neuroprotective and cardioprotective drug candidate NYR-BI03.
Ada Torres
Ada Torres
2 May 2025
Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.
Ada Torres
Ada Torres
30 Apr 2025
Cardiex reports strong early sales momentum for its CONNEQT Pulse device with approximately 3,000 units sold or contracted since its mid-January launch, supported by innovative app features and operational efficiencies. Despite regulatory delays in the US pharma sector and tariff challenges, the company is positioned for scalable growth and category leadership in preventative cardiovascular care.
Ada Torres
Ada Torres
30 Apr 2025
UNITH Ltd reports a 9.3% rise in Q3 FY25 cash receipts driven by its B2C subscription surge and a landmark pharmaceutical contract, alongside strategic platform upgrades and leadership changes.
Sophie Babbage
Sophie Babbage
30 Apr 2025
EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.
Ada Torres
Ada Torres
30 Apr 2025
Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.
Ada Torres
Ada Torres
30 Apr 2025
Invion Limited has progressed its Photosoft clinical programs with new patient dosing and an expanded collaboration with Hanlim Pharm, backed by a successful $2 million share placement to accelerate development.
Ada Torres
Ada Torres
30 Apr 2025